Hoppa till innehål

Ortivus AB: Year-end Report January – December 2025

2026-02-19 08:30

“We enter 2026 with a strengthened balance sheet, a more efficient organisation, and a portfolio of innovations already making a difference.”

October-December 2025

  • Net sales decreased by 12% and amounted to SEK 18.8 (21.3) million.
  • The gross margin increased to 41 (21)%.
  • EBITDA amounted to SEK -3.9 (-4.4) million.
  • Adjusted EBITDA* amounted to SEK -1.6 (2.3) million.
  • Net profit after tax amounted to SEK -7.0 (-9.6) million.
  • Earnings per share before and after dilution amounted to SEK -0.10 (-0.22).

 
January-December 2025

  • Net sales decreased by 9% and amounted to SEK 73.4 (80.4) million.
  • The gross margin amounted to 40 (35)%.
  • EBITDA amounted to SEK -15.9 (-13.8) million.
  • Adjusted EBITDA* amounted to SEK -8.6 (-4.9) million.
  • Net profit after tax amounted to SEK -21.9 (-24.9) million.
  • Earnings per share before and after dilution amounted to SEK -0.43 (-0.56).

 
Significant events during and after fourth quarter

  • The directed rights issue, which was registered on 3 November and fully subscribed, raised SEK 52 million for the Company after transaction costs.
  • Items of a non-recurring nature impacted the quarterly result by SEK 2.2 million. For the full year, non-recurring items amounted to SEK 7.4 million.
  • On 13 January, it was announced that Ponderus Invest AB holds 80 per cent of the Company following the mandatory cash offer made in accordance with the Takeover Code.
  • In February, Minni Raij joined the Company as Chief Financial Officer.
  • The Board of Directors proposes that no dividend be paid for the financial year 2025.

Get in touch

Empower your team with smarter solutions

Discover why leading healthcare organisations are choosing Ortivus.

Get contacted

Fill in the form and one of our sales representatives will contact you as soon as possible.

Required